Shares of Evolus made a doubly bullish move Tuesday — retaking their 50-day and 200-day moving averages — on a strong preliminary fourth-quarter report and guidance for 2025.
The medical aesthetics company preannounced $79 million in fourth-quarter sales, up 30% from the year-earlier period and above forecasts for $76 million to $77 million, Leerink Partners analyst Marc Goodman said in a report.
This helped Evolus top its 2024 outlook. In November, the company lowered its guidance for the year by 1%, leading to a single-day 15% stock dive. Over the course of six days, Evolus stock tumbled 29%.
"After a stock reaction to that November announcement, which we have always thought was confusing and overdone, the company likely makes everyone feel much better with today's PR (press release)," Goodman said. "We really liked the stock at $17 back in November, so we like it even more today at $13-$14 with this kind of announcement."
Evolus stock ramped up 28.3% to 13.48. Shares surged above their 50-day and 200-day lines — a bullish sign — and touched their highest point since early November.
Evolus' 2025 Guidance
In addition to the strong preliminary report, Evolus guided to $345 million to $355 million in sales for 2025, bracketing the Street's view for $352 million, Mizuho Securities analyst Uy Ear said in a note to clients.
The company also now expects the Food and Drug Administration to approve its Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels in the second quarter. These gels help reduce the appearance of fine lines and wrinkles.
Injectable hyaluronic acid gels Evolysse and Estyme are expected to generate 8% to 10% of 2025 sales.
The expected approval will transition Evolus from a single-product company to a "multiproduct innovator," Chief Executive David Moatazedi said in a written statement. Evolus' flagship product is Jeuveau, a neurotoxin filler like AbbVie's Botox.
Botox is easily the market leader — its name synonymous with smoothing wrinkles. As a cosmetic drug, Botox is projected to bring in $761 million in fourth-quarter sales, according to FactSet. But Jeuveau is growing quickly with sales rising 22% to 42% over the past four quarters. Botox cosmetic sales have grown up to 12% over the past four quarters, including one quarter when sales fell 4%.
Follow Allison Gatlin on X/Twitter at @IBD_AGatlin.
